Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.50 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PAM | P19021 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5480906 | 1.00 | FFAR1 (0.50) | FFAR1PPARDPPARANPSR1CHRM2 | |
| SCHEMBL5486388 | 1.00 | FFAR1 (0.50) | FFAR1PPARDPPARANPSR1CHRM2 | |
| SCHEMBL9440070 | 0.92 | FFAR1 (0.45) | FFAR1PPARDPPARANPSR1CHRM2 | |
| SCHEMBL5634911 | 0.90 | FFAR1 (0.54) | FFAR1PPARDPPARACHRM2CHRM1 | |
| SCHEMBL5634910 | 0.90 | FFAR1 (0.54) | FFAR1PPARDPPARACHRM2CHRM1 | |
| SCHEMBL5632476 | 0.87 | FFAR1 (0.52) | FFAR1PPARDPPARACHRM2CHRM1 | |
| SCHEMBL5632474 | 0.87 | FFAR1 (0.52) | FFAR1PPARDPPARACHRM2CHRM1 | |
| SCHEMBL5634669 | 0.85 | FFAR1 (0.50) | FFAR1PPARDPPARACHRM2CHRM1 | |
| SCHEMBL5634667 | 0.85 | FFAR1 (0.50) | FFAR1PPARDPPARACHRM2CHRM1 | |
| SCHEMBL8977007 | 0.81 | FFAR1 (0.48) | FFAR1PPARDPPARACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202213-B2 | Combination therapy using a dual PPAR-α/PPAR-γ activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2007-04-10 | — | — | US | disclosed |
| US-20030199451-A1 | Combination therapy using a dual PPAR-a/PPAR-y activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders | HIGH POINT PHARMACEUTICALS, LLC | 2003-10-23 | — | — | US | disclosed |
| US-6569901-B2 | (E)-(S)-2-Ethoxy-3-(4-(5-phenyl-pent-2-en-4-ynyloxy)-phenyl)-propionic acid, ethyl ester for example; treating conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR); diabetes, obesity | NOVO NORDISK A/S (DK) | 2003-05-27 | — | — | US | disclosed |
| EP-1254102-A1 | ALKYNYLSUBSTITUTED PROPIONIC ACID DERIVATIVES AND THEIR USE AGAINST DIABETES AND OBESITY | Novo Nordisk A/S (DK) | 2002-11-06 | — | — | EP | disclosed |
| US-20010041709-A1 | New compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2001-11-15 | — | — | US | disclosed |
| WO-2001055086-A1 | ALKYNYLSUBSTITUTED PROPIONIC ACID DERIVATIVES AND THEIR USE AGAINST DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
| EP-0608336-B1 | AZABICYCLO ARYLACETYLENE AND ARYLENYNE OXIMES AS CHOLINERGIC AGENTS AND METHODS OF TREATMENT | WARNER LAMBERT CO (US) | 1998-05-20 | — | — | EP | disclosed |
| US-5482938-A | Azabicyclo and azacyclo oxime and amine cholinergic agents and methods of treatment | WARNER-LAMBERT COMPANY (US) | 1996-01-09 | — | — | US | disclosed |
| US-5346911-A | Analgesics, cognition activators, treatment of alzheimer*s s disease | WARNER-LAMBERT COMPANY (US) | 1994-09-13 | — | — | US | disclosed |
| EP-0608336-A1 | AZABICYCLO ARYLACETYLENE AND ARYLENYNE OXIMES AS CHOLINERGIC AGENTS AND METHODS OF TREATMENT | WARNER-LAMBERT COMPANY (US) | 1994-08-03 | — | — | EP | disclosed |
| US-5306718-A | Analgesics, cognition activators | WARNER-LAMBERT COMPANY (US) | 1994-04-26 | — | — | US | disclosed |
| WO-1993008192-A1 | AZABICYCLO ARYLACETYLENE AND ARYLENYNE OXIMES AS CHOLINERGIC AGENTS AND METHODS OF TREATMENT | WARNER-LAMBERT COMPANY (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041709-A1 | New compounds, their preparation and use | PPARG, PPARD, PPARA | FFAR1 19/4885PPARD 2/4885PPARA 3/4885 |
| US-20030199451-A1 | Combination therapy using a dual PPAR-a/PPAR-y activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders | GLP1R, PPARG, PPARA | FFAR1 55/4885PPARD 4/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.